Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Renaparin

Financiado

Cerrado

Improving kidney transplantation outcome with Renaparin for patients with End S...

Improving kidney transplantation outcome with Renaparin for patients with End Stage Renal Disease by attenuating graft ischemia reperfusion injury This project will validate the safety and efficacy of Corline Biomedical’s pharmaceutical compound Renaparin®, a novel cell replacement technology used to coat the lining of the blood vessels of kidneys prior to transplantation.... ver más

31/05/2020

Corline

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

CORLINE BIOMEDICAL AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-31

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

Corline

2.36M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NORMOPERF Normothermic perfusion devices for renal and hepatic preserv... 71K€ Cerrado

RTI2018-099946-B-I00 APLICACION DE TUBULOS BIOARTIFICIALES AL ESTUDIO DE LA INICI... 97K€ Cerrado

MIR182_KIDNEY-TX miR 182 as new Therapeutical Target in Renal Transplantation 261K€ Cerrado

CONVINCE The Comparison of High Dose Heamodiafiltration HDF versus... 7M€ Cerrado

DER2013-50411-EXP LA REGLA DEL DONANTE CADAVER Y LA DONACION DE ORGANOS TRAS L... 40K€ Cerrado

BIOART Training network for developing innovative bio artificial d... 4M€ Cerrado

Duración del proyecto: 39 meses Fecha Inicio: 2017-02-02
Fecha Fin: 2020-05-31

Líder del proyecto

CORLINE BIOMEDICAL AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This project will validate the safety and efficacy of Corline Biomedical’s pharmaceutical compound Renaparin®, a novel cell replacement technology used to coat the lining of the blood vessels of kidneys prior to transplantation. Donor kidneys lack natural blood flow while awaiting transplantation. This can lead to ischemia (a shortage of oxygen and glucose supply to the kidney tissue). When connected to the recipient’s blood flow, this in turn leads to ischemia reperfusion injury (IRI). Given the alarming shortage of organs available for transplantation in the EU and internationally, the prevention of IRI has become a top priority for the transplantation community. Transplantation surgeons and nephrologists emphasise the pressing need for safe and effective technologies which can improve the outcome of kidney transplantation and extend donor criteria. Renaparin® is used when the kidney has been extracted from the donor and is stored in preservation solution awaiting transplantation. There, it binds to, replaces, repairs and protects damaged kidney cells on the endothelium of the vascular wall. As a result, a kidney is less likely to activate the host’s innate immune system, which increases the chances of organ survival and substantially reduces the likelihood of organ rejection. The research performed in preparation of further development of Renaparin® strongly supports the drug’s potential to increase the success of kidney transplantation. The activities proposed in this project will bring Renaparin® through a Phase I/IIa clinical trial in humans. The produced clinical safety data and preliminary clinical efficacy data will constitute the basis for further clinical development and commercialisation of the product. Corline’s strategic focus lies on establishing Renaparin® as a new cell replacement technology in kidney transplantation. This will constitute the cornerstone of Corline’s accelerated growth. The project is the key step to realize this strategy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores